Entasis Therapeutics Holdings Inc.
Index- P/E- EPS (ttm)-1.12 Insider Own43.10% Shs Outstand47.85M Perf Week23.73%
Market Cap106.59M Forward P/E- EPS next Y-1.02 Insider Trans0.00% Shs Float15.09M Perf Month16.18%
Income-51.70M PEG- EPS next Q-0.29 Inst Own10.40% Short Float1.08% Perf Quarter25.86%
Sales- P/S- EPS this Y48.20% Inst Trans-4.17% Short Ratio0.95 Perf Half Y-16.09%
Book/sh0.35 P/B6.26 EPS next Y9.70% ROA-103.70% Target Price2.00 Perf Year-3.10%
Cash/sh0.69 P/C3.18 EPS next 5Y- ROE-145.50% 52W Range1.40 - 3.88 Perf YTD0.00%
Dividend- P/FCF- EPS past 5Y5.70% ROI- 52W High-43.56% Beta1.41
Dividend %- Quick Ratio1.70 Sales past 5Y- Gross Margin- 52W Low56.43% ATR0.08
Employees51 Current Ratio1.70 Sales Q/Q- Oper. Margin- RSI (14)74.45 Volatility2.16% 3.04%
OptionableNo Debt/Eq0.90 EPS Q/Q-10.50% Profit Margin- Rel Volume5.75 Prev Close2.18
ShortableYes LT Debt/Eq0.00 EarningsApr 27 BMO Payout- Avg Volume171.57K Price2.19
Recom3.00 SMA2018.28% SMA5017.40% SMA200-5.23% Volume986,929 Change0.46%
Sep-09-20Initiated Cantor Fitzgerald Overweight $5
Jul-13-20Initiated ROTH Capital Buy $9
May-24-22 03:03PM  
May-23-22 10:04AM  
May-19-22 02:47PM  
May-17-22 08:00AM  
Apr-27-22 07:30AM  
Apr-26-22 08:00AM  
Apr-18-22 08:30AM  
Mar-03-22 07:30AM  
Feb-02-22 04:33PM  
Jan-10-22 08:00AM  
Nov-12-21 06:59AM  
Nov-04-21 07:30AM  
Oct-29-21 07:10AM  
Oct-28-21 08:00AM  
Oct-20-21 10:36AM  
Oct-19-21 09:00AM  
Oct-18-21 04:05PM  
Sep-27-21 11:55AM  
Sep-23-21 04:05PM  
Sep-15-21 04:01PM  
Sep-09-21 08:00AM  
Aug-14-21 05:54AM  
Aug-11-21 04:05PM  
Aug-10-21 08:00AM  
Aug-05-21 04:01PM  
Aug-04-21 04:05PM  
Jul-27-21 08:00AM  
Jul-14-21 08:00AM  
Jul-01-21 08:00AM  
Jun-18-21 08:00AM  
May-05-21 04:05PM  
May-03-21 04:05PM  
Mar-23-21 08:00AM  
Mar-13-21 02:06AM  
Jan-26-21 08:00AM  
Jan-07-21 08:00AM  
Dec-01-20 01:52AM  
Nov-17-20 08:00AM  
Nov-05-20 04:05PM  
Oct-14-20 08:00AM  
Oct-08-20 08:32AM  
Sep-10-20 08:00AM  
Aug-28-20 08:00AM  
Aug-06-20 04:05PM  
Aug-05-20 08:00AM  
Jul-13-20 10:05AM  
Jul-06-20 08:00AM  
Jun-22-20 09:48AM  
Jun-18-20 08:00AM  
Jun-11-20 04:05PM  
May-18-20 11:34AM  
May-07-20 04:05PM  
Apr-22-20 04:05PM  
Mar-13-20 07:46AM  
Mar-11-20 04:05PM  
Dec-19-19 09:49AM  
Nov-24-19 01:56PM  
Nov-14-19 07:30AM  
Oct-30-19 04:05PM  
Oct-29-19 08:30AM  
Oct-03-19 04:01PM  
Oct-01-19 10:07AM  
Sep-30-19 01:00AM  
Sep-19-19 11:56AM  
Sep-03-19 08:00AM  
Aug-12-19 07:30AM  
Aug-06-19 08:00AM  
Jul-01-19 09:13AM  
Jun-27-19 08:00AM  
Jun-24-19 08:00AM  
Jun-20-19 11:13AM  
Jun-18-19 04:01PM  
Jun-13-19 08:00AM  
Jun-10-19 08:00AM  
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Perros ManoussosSee RemarksOct 19Sale3.1911,97438,197147,526Oct 20 04:14 PM
Mueller John PatrickChief Development OfficerOct 19Sale3.194,00112,76345,999Oct 20 04:10 PM
Gutch MichaelSee RemarksOct 19Sale3.193,75911,99146,241Oct 20 04:09 PM
Keiley Elizabeth MGeneral CounselOct 19Sale3.193,75911,99146,241Oct 20 04:08 PM
Tommasi RubenChief Scientific OfficerOct 19Sale3.193,75911,99168,265Oct 20 04:08 PM
Altarac DavidChief Medical OfficerOct 19Sale3.193,75911,99146,241Oct 20 04:06 PM
Ronsheim MatthewSee RemarksOct 19Sale3.193,75911,99146,241Oct 20 04:05 PM
Innoviva, Inc.10% OwnerJun 11Buy2.006,268,97512,537,95010,000,000Jun 11 05:39 PM